In The News

Applied BioMath, LLC Unveils the use of Mathematical Modeling in ADC therapeutics at the 7th Annual World ADC Conference

Updated 12/13/2016: Applied BioMath awarded Best Poster award at World ADC 2016!

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that they will deliver a presentation and poster at the 7th annual World ADC conference on the use of quantitative systems pharmacology (QSP) modeling to understand the pharmacokinetics (PK) of antibody drug conjugate (ADC) therapeutics.

Applied BioMath, LLC presenting at two international Systems Medicine conferences in Kiel, Germany

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the Annual e:Med Meeting on Systems Medicine 2016 in Kiel, Germany on October 4-6, 2016. Dr.

Applied BioMath, LLC announces Jounce Therapeutics has selected their Team for Clinical Trial Support for the JTX-2011 ICONIC Trial

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug invention, today announced an agreement with Jounce Therapeutics for clinical pharmacology and quantitative systems pharmacology (QSP) modeling and simulation support for Phase 1 clinical trials.

Applied BioMath will:

Applied BioMath, LLC awarded Small Business of the Year Award 2016

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, has been named a Top 10 small, high growth business in the Greater Boston area by the Greater Boston Chamber of Commerce. This award honors businesses that demonstrate achievement in management, workplace excellence, product innovation, and social responsibility.

Applied BioMath, LLC presents and moderates at SIAM Conference on the Life Sciences 2016

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced their participation in the SIAM Conference on the Life Sciences which was held July 11-14, 2016 in Boston, MA.

Dr. John Burke featured in CEO/CFO Magazine

Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, LLC was recently featuerd in CEO/CFO magazine. Lynn Fosse, Senior Editor of CEOCFO Magazine interviewed Dr. Burke to learn about how Applied BioMath is revolutionizing drug invention, why its technology is different than anything offered today, and examples where Applied BioMath helped optimize and accelerate drug development.

Read Dr. Burke's interview in CEO/CFO Magazine

Applied BioMath, LLC awarded $1.5M from NIH for Systems Modeling in Biotherapeutic Development

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that the National Institutes of Health (NIH) has awarded a $1.5M grant to Applied BioMath to enhance the company's proprietary tools and algorithms for analyzing nonclinical data and mechanisms and predicting clinical PKPD for biologics.

Applied BioMath, LLC to sponsor and moderate at Cancer Advance Boston 2016

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced that they will sponsor, moderate, and participate in Cancer Advance Boston 2016. Cancer Advance, being held April 4-5 at Harvard Medical School, brings together distinguished cancer experts from academia and industry, alongside the people who help turn discoveries into therapies for a high-energy, uniquely interactive meeting focused on the latest in cancer research.

Inaugural QSP-SB Industry & Academia Symposium Poster Session

1st Place in the Student Category: Nikolaos Tsamandouras & 1st Place in the Non-student Category: Jangir Selimkhanov

Applied BioMath, LLC expands QSP-SB Industry and Academia Symposium to include poster session sponsored by Pfizer Inc.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, is pleased to announce the third and final QSP-SB Industry and Academia Symposium of the 2015-2016 academic year will expand to include an inaugural poster session, sponsored by Pfizer Inc.

Applied BioMath, LLC announces live webinar on Quantitative Systems Pharmacology Modeling (QSPM) in Immuno-oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced an upcoming live webinar: “Quantitative Systems Pharmacology Modeling (QSPM) Case Study in Immuno-oncology”

ISoP NE and Applied BioMath to co-host March QSP Social in Cambridge, MA

Kick-off March with a fun evening of food, drinks, and conversations with your peers! Join us for our next QSP Social.

Applied BioMath holds its full-day Science and Strategy Meeting

Applied BioMath's Scientific and Executive Leadership Teams recently spent the day at our Science and Strategy offsite. We reflected on 2015 projects, shared new science and technologies, and officially kicked off 2016. We are extremely proud of what we achieved in 2015, and we will work diligently to continue that momentum into and throughout 2016!

Applied BioMath welcomes Werner Meier to its Scientific Advisory Board

Applied BioMath (www.appliedbiomath.com) is thrilled to announce that Werner Meier is the newest member of its Scientific Advisory Board, which comprises pioneers and thought leaders in the mathematical modeling, biological engineering, biotechnology, and medical fields. Werner joins key opinion leaders Douglas Lauffenburger, PhD, Dr. Joseph Loscalzo, MD, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD.

Applied BioMath, LLC announces collaboration with Zymeworks Inc.

Applied BioMath, LLC (www.appliedbiomath.com) today announced a collaboration with Zymeworks Inc. (www.zymeworks.com), a leader in the development of bi-specific antibodies, to leverage Applied BioMath's proprietary analytical and predictive capabilities in quantitative systems pharmacology.

Applied BioMath announces annual Charitable Giving Program

At Applied BioMath, we believe strongly in giving back to our community. One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team.

Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board

Applied BioMath is thrilled to announce that Dr.Joseph Loscalzo, MD, PhD is the newest member if its Scientific Advisory Board. Dr. Loscalzo is chair of the Department of Medicine and physician-in-chief at Brigham and Women's Hospital (BWH). A cardiovascular medicine specialist, he is also the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS).

Applied BioMath, LLC to Present and Exhibit at the Drug Development Bootcamp

Applied BioMath (www.appliedbiomath.com), a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will present and exhibit at the Drug Development Bootcamp onNovember 17-18, 2015 at The Harvard Club in Boston, MA.

Top Pharma and Biotech Researchers meet with local Academics for QSP-SB Industry & Academia Symposium

Applied BioMath (www.appliedbiomath.com) announces the kick-off of the 2015-2016 QSP-SB Industry & Academia Symposium series. This week, top pharma and biotech representatives will meet along with local faculty, students, and post docs, for the Fall QSP-SB Industry & Academia Symposium.

Dr. Josh Apgar's research published in Molecular Cancer Therapeutics

This publication appears in the October 2015 edition of Molecular Cancer Therapeutics

Applied BioMath, LLC. To Sponsor and Present at the Inaugural Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015

Applied BioMath, a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will sponsor and present at the Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015 on September 23-24 in Boston, MA. Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present “QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials” on Thursday September 24, 2015 at 12:10 PM.

Applied BioMath cohosts Inaugural QSP/SB Academia-Industry Seminar with MIT Biological Engineering Department

Applied BioMath and the MIT Biological Engineering Department recently held the inaugural QSP/SB Academic-Industry Symposium at the MIT State Center in Camrbidge, MA. The QSP/SB Academic-Industry Symposium is an ongoing academic-industry forum to discuss systems biology and quantitative systems pharmacology projects, challenges, and opportunities.

Dr. John Burke to present at QSP Congress Boston 2015

Dr. John Burke, Co-Founder, President, and CEO of Applied Biomath, will present "QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials" at QSP Congress Boston 2015.

Following are the key focal points of Dr. Burke's presentation:

New Applied BioMath Publication: An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates

Applied BioMath is proud to announce its most recent publication, An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates, published in the July 2015 edition of Pharmaceutical Research.

Applied BioMath Succeeds to Raise $1.36 Million

Applied BioMath, an advanced mathematical modeling software for pharmaceutical research and development has recently raised $1,360,000 of funding.